Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 80,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 80,000 shares of Natera stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the transaction, the insider now owns 117,560 shares of the company’s stock, valued at $10,676,799.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $85.28 on Friday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82. The stock has a market cap of $10.30 billion, a price-to-earnings ratio of -22.50 and a beta of 1.37. The stock’s 50 day moving average price is $86.05 and its 200 day moving average price is $65.85. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Equities research analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on NTRA shares. Stephens reissued an “overweight” rating and issued a $78.00 target price on shares of Natera in a report on Tuesday, January 30th. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and raised their target price for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. The Goldman Sachs Group raised their target price on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, April 15th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a report on Friday, April 5th. Finally, BTIG Research raised their target price on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Friday, December 29th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after buying an additional 588,147 shares during the last quarter. JPMorgan Chase & Co. grew its position in Natera by 0.9% in the third quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock worth $334,388,000 after buying an additional 67,102 shares during the last quarter. State Street Corp grew its position in Natera by 20.4% in the second quarter. State Street Corp now owns 3,409,372 shares of the medical research company’s stock worth $120,828,000 after buying an additional 577,106 shares during the last quarter. Alliancebernstein L.P. grew its position in Natera by 55.5% in the second quarter. Alliancebernstein L.P. now owns 3,072,466 shares of the medical research company’s stock worth $149,506,000 after buying an additional 1,096,964 shares during the last quarter. Finally, Kynam Capital Management LP grew its position in Natera by 3.6% in the third quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock worth $132,912,000 after buying an additional 103,668 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.